For FY25, Astellas Pharma guided for just 3% revenue growth. FY25 core operating profit is expected to decline 10%, while net profit is anticipated to take a bigger hit and decrease 17%.
What is covered in the Full Insight:
Financial result of Astellas in FY24
Impairment loss affecting FY24 profits
Astellas's revenue outlook for FY25
Impact of upcoming patent cliff
Astellas share price analysis
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.